VF in the News

FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease

Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...

Read more

Early VF-Funded Study Paves Way for New ANCA Vasculitis Clinical Trial

More than a decade ago, Donna O’Dell Bunch, PhD, was co-investigator in a Vasculitis Foundation-funded trial that studied changes in B cells (white blood cells that form antibodies) in patients with ANCA-associated vasculitis, and the medical implications of those changes on the disease. The findings from that 2007 clinical trial,…...

Read more

New VF Board Member Jacquelyn Eidson Hopes to Advocate for Rural Patients

Author: Nina Silberstein Jacquelyn (Jacque) Eidson wanted to serve on the VF Board of Directors because she knows firsthand the impact that vasculitis has on patients, and those who love them. Jacque’s father-in-law was diagnosed with vasculitis nearly 15 years ago and she believes his medical journey was much different…...

Read more